Health News Releases

  • Today November 13
October 27, 10:08
Dong-A ST Highlights Preclinical Promise of Topical Icotrokinra for Psoriasis Treatment
Dong-A ST Co., Ltd. (https://www.donga-st.com/en/) (President and CEO Jae-hoon Jeong, KRX: 170900) announced that it presented preclinical research findings demonstrating the potential of a topical fo
David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck
October 27, 09:09
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (T
October 25, 15:25
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
BeOne Medicines Ltd. (https://beonemedicines.com/)(Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines ac
October 25, 14:25
Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 2026
Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult pat
October 25, 13:25
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis o
October 25, 13:05
Brenus Pharma’s Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS
October 25, 12:40
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: I
October 23, 15:40
SBC Medical Initiates Development of a DNA Methylation Test to Estimate Biological Age
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, tod
October 23, 15:22
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the comp
October 23, 11:40
Future Health and Bridge for Billions to Launch Programme Strengthening Health Entrepreneurship in Emerging Markets
Future Health - A Global Initiative by Abu Dhabi and Bridge for Billions will launch a new entrepreneurship programme designed to strengthen promising health ventures in emerging markets and help loca
October 22, 14:48
Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026. · Record net sales of 4.765 billion USD for the fir
October 22, 10:00
MindWalk Screens 890,634 Antibody Sequences for Immune Risk in Under Five Hours
MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a Bio-Native AI company, today published a white paper showing that its LensAI™ immunogenicity screening ran across an entire public antibody datab
October 22, 09:53
Merck Collaborates with NVIDIA, Microsoft and Dawn Health to Develop Novel Support Model for People Living with Rare Tumors
Merck, a leading science and technology company, today announced a collaboration with NVIDIA Corporation (Santa Clara, California, USA), Microsoft Corporation (Redmond, Washington, USA) and Dawn Healt
October 22, 09:40
Global Network for the Advancement of Metabolic Psychiatry (MetPsy) Launches with $20 Million Investment in Clinical Care, Education and Research at McLean Hospital
Baszucki Group today announced the launch of the Global Network for the Advancement of Metabolic Psychiatry (MetPsy (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fmetpsy.com%2Fannou
October 21, 17:30
Inaugural Future Health Impact Challenge Documentary Released as Expressions of Interest Open for Second Challenge
Future Health - A Global Initiative by Abu Dhabi today premiered a documentary film about the inaugural Future Health Impact Challenge during the first day of the Abu Dhabi Future Health Summit. The f
October 21, 15:53
AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership
Galderma (SIX: GALD) will showcase data from its leading innovative Injectable Aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) taking place in Dubai, United Arab Emir
October 21, 13:55
Roquette Brings Broad Portfolio of Excipient Solutions and Technical Expertise to AAPS PharmSci 360 2026
Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will showcase its expansive portfolio of excipients, capsules, coatings, and biopharma solutions at AAPS
October 21, 09:50
Parse Biosciences Launches Evercode MAX, Enabling Researchers to Profile More Cells and Samples with Greater Flexibility
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fparsebiosciences.com&esheet=54624785&newsitemid=20261020402612&lan=en-US&anchor=Parse+Biosciences&index=1&md5=365fc2
October 20, 16:47
Hologic Signs Definitive Agreement to Acquire Reveal Genomics
Hologic, a global leader in women’s health, today announced that it has signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, that develops
October 20, 16:40
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the Eu
October 20, 14:40
Sultan bin Ahmed Launches 60-Home Village Project, Inaugurates Orphanage and Clinic in Southern Philippines
A 60-home village planned for Dinas on the southern Philippine island of Mindanao will provide housing, clean water and vocational training under a humanitarian programme supported by organisations ba
October 20, 09:50
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54623752&newsitemid=20261019826127&lan=en-US&anchor=TSE%3A4
October 18, 11:05
Future Health Launches Global Challenge to Move Health Innovation Towards Real-world Application
Future Health - A Global Initiative by Abu Dhabi opened applications for the Future Health Digital Innovation Challenge 2026, welcoming innovators from around the world to develop AI, software, and co
October 16, 14:30
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54621245&newsitemid=20261014178348&lan=en-US&anchor=TSE%3A4
October 16, 12:00
New Study Brings Ketogenic Therapy for Bipolar Disorder Directly to Rural Alabama Homes
Baszucki Group today announced funding for a clinical study to examine the impact of ketogenic therapy on people living with bipolar disorder in rural Central Alabama. This study, led by researchers a
25 per page50 per page75 per page100 per page